Regeneron Pharmaceuticals
The Principal Pathologist provides critical pathology expertise across the drug development continuum, supporting the discovery, characterization, and preclinical development of diverse therapeutic modalities. This role involves serving as the study pathologist for in-house discovery studies, producing high-quality pathology reports, and conducting peer reviews for toxicology studies. The position requires close collaboration with research scientists to advance innovative medicines from discovery through development.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago